I have revenue of $100M with just 10% of the market in the US for DLBCL (18K diagnosis yearly using conservative treatment cost which is currently quite expensive) and Cholangiocarcinoma (8K diagnosis yearly using conservative treatment cost which is currently quite expensive) and the average EPS ratio for biotech stock is 10-15 (some says it's as high as 20). So maybe I'm wrong and it's really worth $2B and not $1B.......
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.001(7.69%) |
Mkt cap ! $104.5M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.4¢ | 1.2¢ | $267.3K | 20.57M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 788815 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 13241534 | 29 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |